C World Wide Group Holding A Iovance Biotherapeutics, Inc. Transaction History

C World Wide Group Holding A

$8.2 Billion
Q4 2024

A detailed history of C World Wide Group Holding A transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, C World Wide Group Holding A holds 1,260,000 shares of IOVA stock, worth $5.09 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

1,260,000

Previous 1,260,000 -0.0%

Holding current value

$5.09 Million

Previous $11.8 Million 21.19%

% of portfolio

0.11%

Previous 0.12%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$7.78 - $14.19 $1.56 Million - $2.84 Million	200,000 Added 18.87%	1,260,000 $10.1 Million
Q1 2024 May 03, 2024	SELL	$7.59 - $17.47 $2.28 Million - $5.24 Million	-300,000 Reduced 22.06%	1,060,000 $15.7 Million
Q4 2022 Feb 03, 2023	BUY	$5.62 - $10.0 $1.12 Million - $2 Million	200,000 Added 17.24%	1,360,000 $8.69 Million
Q2 2022 Aug 02, 2022	BUY	$6.38 - $18.33 $7.4 Million - $21.3 Million	1,160,000 New	1,160,000 $12.8 Million
Q2 2019 Aug 02, 2019	SELL	$9.78 - $24.52 $2.22 Million - $5.56 Million	-226,681 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$7.51 - $11.93 $1.31 Million - $2.07 Million	-173,922 Reduced 43.42%	226,681 $2.01 Million
Q3 2018 Nov 05, 2018	BUY	$11.25 - $17.7 $170,516 - $268,278	15,157 Added 3.93%	400,603 $4.51 Million
Q2 2018 Aug 03, 2018	BUY	$12.45 - $16.95 $4.8 Million - $6.53 Million	385,446 New	385,446 $4.93 Million

Others Institutions Holding IOVA

# of Institutions

342

Shares Held

247M

Call Options Held

2.51M

Put Options Held

3.5M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $638M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of C World Wide Group Holding A, based on Form 13F filings with the SEC.

News

Stay updated on C World Wide Group Holding A with notifications on news.

Account

C World Wide Group Holding A Iovance Biotherapeutics, Inc. Transaction History